Rating Change
Citizens reiterated its Market Outperform rating on Opus Genetics, Inc. (NASDAQ:IRD) on October 16, 2026.
reiterateNASDAQ:IRD
Citizens Reiterates Market Outperform Rating on Opus Genetics, Inc. (IRD)
Citizens reiterated its Market Outperform rating on Opus Genetics, Inc. (NASDAQ:IRD) on October 16, 2026.
At publication ·
What changed
Opus Genetics, Inc. (NASDAQ:IRD) · reiterate
- Firm
- Citizens
- Rating
- Market Outperform to Market Outperform
- Price at event
- $3.84
- Market capitalization
- $167.9M
At a glance
Key takeaways
- Opus Genetics trades at $3.83 with a market cap of $167.9M and has gained 102.5% over the past 52 weeks.
Market Context
Opus Genetics, Inc. operates in the Healthcare sector. The stock currently trades at $3.83 with a market capitalization of $167.9M. The stock has gained 102.5% over the past 52 weeks.
Analyst coverage from Citizens provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Opus Genetics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Opus Genetics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 16, 2026 | Citizens | Market Outperform | N/A |
| Oct 06, 2026 | Jones Trading | Buy | N/A |
| Oct 02, 2026 | Chardan Capital | Buy | N/A |
| Sep 10, 2026 | Wedbush | Outperform | N/A |
| Sep 09, 2026 | Chardan Capital | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View IRD Stock Page
Frequently Asked Questions
What does the Market Outperform rating mean for IRD?
A rating of Market Outperform from Citizens reflects the analyst's outlook on Opus Genetics, Inc. (NASDAQ:IRD). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the IRD forecast page.